| 产品名称： | BC-3 |
|---|---|
| 商品货号： | TS212602 |
| Organism： | Homo sapiens, human |
| Tissue： | Pleura, pleural effusion |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain Kaposis sarcoma-associated herpesvirus genome
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | lymphoma |
| Age： | 85 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | This cell line is a suitable transfection host. It is ideal for the isolation and study of KSHV. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL). BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman. |
| Clinical Data： | 85 years
Caucasian
male
|
| Antigen Expression： | CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 - |
| Comments： | The BC-3 cell line contains the viral genome for Kaposis sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8). KSHV is a recently identified and partially uncharacterized virus. BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV). They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV). The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV.
BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate. The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage-restricted antigens.
The cells do express activation antigens. |
| Complete Growth Medium： | RPMI 1640 medium, 80%; fetal bovine serum, 20%
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 105 viable cells/mL. Maintain cell density between 5 x 105 and 2 x 106 viable cells/mL. Medium Renewal: 2 to 3 times a week. xa0 |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 12 D5S818: 11,12 D7S820: 10,12 THO1: 6,9 TPOX: 8,11 vWA: 14,18 |
| Name of Depositor： | Cornell Res. Fndn., Inc. |
| U.S. Patent Number： | |
| Year of Origin： | 1995 |
| References： | Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposis sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859 Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | BC-3 |
|---|---|
| 商品货号： | TS212602 |
| Organism： | Homo sapiens, human |
| Tissue： | Pleura, pleural effusion |
| Cell Type： | B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2 xa0Cells contain Kaposis sarcoma-associated herpesvirus genome
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | lymphoma |
| Age： | 85 years |
| Gender： | male |
| Ethnicity： | Caucasian |
| Applications： | This cell line is a suitable transfection host. It is ideal for the isolation and study of KSHV. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL). BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman. |
| Clinical Data： | 85 years
Caucasian
male
|
| Antigen Expression： | CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 - |
| Comments： | The BC-3 cell line contains the viral genome for Kaposis sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8). KSHV is a recently identified and partially uncharacterized virus. BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV). They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV). The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV.
BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate. The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage-restricted antigens.
The cells do express activation antigens. |
| Complete Growth Medium： | RPMI 1640 medium, 80%; fetal bovine serum, 20%
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 105 viable cells/mL. Maintain cell density between 5 x 105 and 2 x 106 viable cells/mL. Medium Renewal: 2 to 3 times a week. xa0 |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 12 D5S818: 11,12 D7S820: 10,12 THO1: 6,9 TPOX: 8,11 vWA: 14,18 |
| Name of Depositor： | Cornell Res. Fndn., Inc. |
| U.S. Patent Number： | |
| Year of Origin： | 1995 |
| References： | Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposis sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859 Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999 |
